← Leaderboards
Josep Maria Domingo-Domenech
Mayo Clinic Rochester
$5,429,135
Attributed
$6,913,684
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,913,684 · 5
By mechanism
R01$6,913,684 · 5
Top collaborators
- Veronica Rodriguez-Bravo4 shared
- Zhenkun Lou2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Veronica Rodriguez-Bravo$4,467,659
- Zhenkun Lou$18,569,951
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientAndrogen ReceptorResistanceSignal TransductionMalignant NeoplasmsMolecularMalignant Neoplasm Of ProstateSignal PathwayGenesProstateTherapy ResistantTranscription FactorCellsGenetic TranscriptionSamplingIn VivoProgramsNeoplasm Circulating CellsAutomobile DrivingOncogenicClinically RelevantData SetCancer CellComplex
Grant awards (17)
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors$532,649
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer$492,046
R01 · FY2025 · CA
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer$454,404
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer$452,180
R01 · FY2025 · CA · contact PI
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors$532,649
R01 · FY2024 · CA · contact PI
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer$507,395
R01 · FY2024 · CA
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer$452,180
R01 · FY2024 · CA · contact PI
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer$434,911
R01 · FY2024 · CA · contact PI
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer$452,824
R01 · FY2023 · CA · contact PI
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer$348,785
R01 · FY2021 · CA · contact PI
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer$93,163
R01 · FY2021 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$395,976
R01 · FY2020 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$387,799
R01 · FY2019 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$425,854
R01 · FY2018 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$243,617
R01 · FY2017 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$228,615
R01 · FY2017 · CA · contact PI
Role of GATA2 signaling network in Lethal Prostate Cancer$478,637
R01 · FY2016 · CA · contact PI